CMA hails new draft legislation
COMPLEMENTARY Medicines Australia (CMA) has welcomed the release of the “exposure draft” of the Therapeutic Goods Amendment (2017 Measures No. 1) Bill 2017 which includes amendments to provide a new approval pathway for listing complementary medicines with higher therapeutic indications and health claims.
CMA ceo Carl Gibson said the measure aimed to reward greater investment in R D by industry, providing an incentive to further expand the clinical research base for complementary medicines.
He said the use of traditional and complementary medicines (CMs) is growing worldwide, with a supportive business environment set to help the Australian CM sector continue its rapid growth, support local innovation-rich manufacturing and Australian based research.